BOVIE MEDICAL CORP
8-K, 1999-04-15
INDUSTRIAL ORGANIC CHEMICALS
Previous: FIDELITY CALIFORNIA MUNICIPAL TRUST, N-30D, 1999-04-15
Next: BOVIE MEDICAL CORP, 10KSB, 1999-04-15



                                                                




SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.  20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

May 8, 1998
(Date of earliest
event reported)

BOVIE MEDICAL CORPORATION
(Formerly known as An-Con Genetics, Inc.)
(exact name of registrant)

DELAWARE
(State or other Jurisdiction
of incorporation)

0-12183
(Commission
File Number)

11-2644611
(IRS Employer
Identification Number)

734 Walt Whitman Road
Melville, NY 11747
(address of principal executive officer)

Registrant's telephone number
including are code (516) 421-5452

One Huntington Quadrangle
Melville, NY  11747
 (former name or former address, if changed
since last report)


THE INFORMATION TO BE INCLUDED IN THE REPORT.

Item 2. Acquisition of Assets.

                          On  May 8,  1998,  the  Registrant  entered  into  and
consummated a strategic alliance agreement with Maxxim
Medical, Inc., ("Maxxim"), a Delaware corporation the shares of which are listed
on the New York Stock Exchange,  which agreement provided for the acquisition by
the Registrant of the trademark "Bovie", a supply,  license and  distributorship
arrangement concerning  electrosurgical  devices and the acquisition of Maxxim's
electrosurgical  generator  product  line in exchange  for  3,000,000  shares of
common stock of The Registrant.  More  specifically,  the agreement provides for
(a) an irrevocable royalty-free sub-license to Maxxim to use the "Bovie" name on
any  electrosurgical  products  marketed  by  Maxxim;  (b)  a  2-year  exclusive
distributorship in Maxxim to resell the Bovie electrosurgical  generator product
line anywhere in the world, and (c) a non-exclusive  right to Maxxim to sell the
Registrant  products  anywhere  in the world.  The  distributorship  arrangement
provides for  anticipated  cooperation  between Maxxim and the  Registrant  with
respect to research and  development  of new  products  and  Maxxim's  option to
become the exclusive distributor thereof.  Maxxim also agreed to certain minimum
purchase orders for the Bovie generator  product line, the Aaron 1200 generators
and other the Registrant products and accessories  aggregating $3,000,000 during
the initial  5-year term of the  agreement,  subject to quality  control and the
Registrant's ability to meet commercially  reasonable purchase orders of Maxxim.
Kenneth  Davidson,  the  chairman of the Board of Maxxim,  has been  appointed a
member of the Board of Directors of the Registrant.

As consideration for the foregoing,  the Registrant  agreed to exchange  
3,000,000 shares of common stock for the Bovie  Electrosurgical  Generator line,
the "Bovie" trademark and tradename,
and  entered  into  agreements  for  the  aforementioned  supply,  license,  and
distributorship  arrangement  involving  Maxxim's  commitments  to purchase  the
Registrant's  current  and  future  products.  Due to the  Registrant's  lack of
sufficient authorized shares, in lieu of common stock, the Registrant has issued
a secured  convertible  promissory  note to Maxxim  in the  principal  amount of
$3,000,000  due on May 7,  2008,  bearing  interest  at the rate of 1% above the
prime  lending rate in effect at Nations Banc  Montgomery  Securities  LLC which
provides for ten annual  payments of principal  and interest  commencing  May 7,
1999. Subject to approval of shareholders increasing the registrant's authorized
capitalization,  scheduled to take place no later than  September 6, 1998,  this
note which is secured by the Registrant's equipment and machinery and inventory,
will be exchanged for  3,000,000  shares of Common Stock of  registrant.  In the
event,  the  shareholders  fail to  authorize  the  increase as  requested,  the
Registrant  will be forced to seek alternate  financing to meet its  obligations
under  the  note.  No  assurance  can be  given  it will be  successful  in such
endeavor.

Item 7.  Financial Statements, Pro-Forma Financial Information and Exhibits.
                  (a) Financial Statements of Businesses Acquired.
                           (Not Applicable)

                  (b) Pro Forma Financial Information.
                           (Not Applicable)
Signature

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  is duly  caused  this  report  to be  signed  on its  behalf  by the
undersigned hereunto duly authorized.

Bovie Medical Corporation
(Formerly known as An-Con Genetics, Inc.)



by  s/Andrew Makrides
   ------------------
         Andrew Makrides, President

Date:   April 14,1999






© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission